RxDoctor Payments Data

Daniel Barton, MD

Nephrology · Canfield, OHNPI 1063488096

Payments from drug & device makers

$3,201in general payments, 2019–2025

Across 165 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$638
  • Amgen$397
  • Otsuka America Pharmaceutical, Inc.$297
  • AstraZeneca$283
  • Vifor Pharma, Inc.$250
  • Travere Therapeutics, Inc.$229
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,06796%
  • Education$1334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,201 in reported general payments places this provider in the 65th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$255,032
Medicare patients
461
Services billed
1,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol202$203,335
JardianceEmpagliflozin87$104,751
VeltassaPatiromer Calcium Sorbitex34$36,493
KerendiaFinerenone19$28,543
LokelmaSodium Zirconium Cyclosilicate14$17,948
Calcitriol358$9,443
Bumetanide81$2,758
Paricalcitol14$2,371
Olmesartan Medoxomil92$1,673
Chlorthalidone74$1,359
Potassium Chloride68$1,344
Labetalol Hcl16$1,197
Nifedipine ErNifedipine31$1,049
Amlodipine Besylate230$967
Metoprolol Succinate52$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$283$221,282216 claims
BayerKerendia$638$28,54319 claims
ANI Pharmaceuticals, Inc.Valsartan$24$79635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 nephrology providers in Ohio.

Other nephrology in Canfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →